CIK 0001878313
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MAIA Biotechnology, Inc.
Sign in to watch- Ticker
- MAIA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 312-416-8592
- Business address
- 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
- 4 Open-market buy Director bought 40,849 shares at $1.22 ($49,999)
- 4 Open-market buy Director bought 81,699 shares at $1.22 ($100,000)
- 4 Open-market buy Director bought 13,740 shares at an average $1.20 ($16,441)
- 4/A Open-market buy Chief Executive Officer bought 10,500 shares at $0.97 ($10,144)
- 4/A Open-market buy Chief Executive Officer bought 72,000 shares at an average $1.11 ($79,849)
- 4 Open-market buy Chief Executive Officer bought 72,000 shares at an average $1.11 ($79,849)
- 4 Open-market buy Director bought 38,145 shares at an average $1.10 ($41,846)
- 4 Open-market buy Director bought 15,000 shares at $1.04 ($15,582)
- 4 Open-market buy Director bought 10,000 shares at $0.98 ($9,785)
- 4 Open-market buy Chief Executive Officer bought 10,500 shares at $0.97 ($10,144)
- 4 Open-market buy Director bought 25,000 shares at an average $0.98 ($24,600)
- 4 Open-market buy Chief Executive Officer bought 11,800 shares at an average $0.98 ($11,547)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 19,230 shares at $1.30 ($24,999)
- 4 Derivatives Options or other derivatives
Page 3 of 13 · 248 filings